• Articles
    • Views
    AUTHOR

    Samantha Freidin

    Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Author's Posts

  • In an age where celebs own tequila brands, this one owns a hangover cure

    We often underestimate the business prowess of influencers and actors, but they do a hell of a lot more than just look pretty. One of those celebs is Shay Mitchell who you may recognise as Emily Fields from Pretty Little Liars, or more recently, as Peach Sallinger in the Netflix series You. Mitchell has garnered

    Read More
    Public
  • Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap

    “Sorry, but what the f**k is the point of a first home buyers scheme if we need another first home buyers scheme to access it?” That was the question that came out of my best friend’s mouth whilst we waited for our post-pilates morning lattes today. It’s been bouncing around in my brain as IRead More
    Public
  • This company is offering DNA tests for the whole family, including the dog!

    Ever wondered if your brother is really your brother? Or what breeds make up your dog (who was advertised by the rescue as ‘mixed breed blend’, I kid you not)?  DNA testing has all the answers you seek, and with the technology becoming cheaper and scalable, direct-to-consumer DNA testing kits are now readily available.  Leaders

    Read More
    Public
  • Virtus Health gains market share in IVF space as demand continues to grow

    It’s not up for debate- a woman’s body is her own. And yet, lots of people have lots to say about women’s bodies and what they should and shouldn’t be able to do.  With the abortion debate at boiling point in America following a major backwards step in legislation, the rights of women are yet

    Read More
    Public
  • Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA

    Rhythm Biosciences (ASX: RHY) is a step closer to commercialising their bowel cancer detection test, having submitted documents to the Australian Therapeutic Goods Administration (TGA) for approval. The filing is a significant milestone for the Company who are hoping to launch their product to market later this year.  Rhythm’s test offers a convenient and non-invasive

    Read More
    Public
  • Green Whistle makes its way to Whistler and beyond in new Canada distribution deal

    The opioid epidemic has been an issue for years now. Since 1990 over half a million deaths have been attributed to opioid overdose. Primarily mediatised as an ‘American’ problem, opioid misuse is significant in most developed countries.  Most people begin their dependence on opioids following surgery where the drugs are prescribed as a method of

    Read More
    Public
  • This company might have the answer for vitiligo

    Winnie Harlow isn’t just a model. She’s a trailblazer, breaking barriers and crushing beauty standards as the first supermodel with vitiligo. The depigmentation disorder of the skin results in progressive loss of epidermal melanocytes (the cells that pigment the skin). Winnie’s unique look has seen her grace the covers of Vogue and Harper’s Bazaar, as

    Read More
    Public
  • US-based heart centre to trial Artrya’s software for heart disease diagnosis

    Coronary heart disease is the most prevalent type of heart disease and the leading single cause of death in Australia, representing 11% of all deaths in 2018. 42% of coronary heart disease related deaths resulted from a heart attack.  Medtech company Artrya (ASX: AYA) is working to improve diagnosis of this often silent disease. Their

    Read More
    Public
  • This Company is using tech to enhance how we care for our ageing population

    Caring comes naturally to us, but with an ageing population, caring can be taxing. The Australian Bureau of Statistics reported that as of 2021, people aged 65 and over outnumbered those under 15. Lower fertility rates and increased life expectancy have been primary drivers of this trend. Whilst it is fantastic to know that, statistically

    Read More
    Public
  • Travel is course correcting. Are these ASX listed companies still struggling, or on sale?

    Contrary to Superhero’s assault of beach themed ads for summer trading, there was little ‘ASX on the beach’ this past summer. Unless of course, you count the shores of St Kilda… which have nothing on Thailand… *sigh* Things may be looking up for this coming summer, and no one is more pleased than the listed

    Read More
    Public
  • Temple & Webster renovates business model, jumping into $26 billion home improvement market

    With so much time stuck inside over the past few years (!!), my apartment got quite the facelift. Where there once would have just been a simple IKEA ensemble is now a well considered symphony of Pinterest worthy elements sourced from all over. ‘Nesting’, as I like to call it, has become something of a

    Read More
    Public
  • Theranos, but make it legit.. Does this company have the answer to cancer detection via blood test?

    Treating cancer is a primary goal of many biotech companies, but for any treatment to begin, physicians need a definitive diagnosis. We know that time is critical in disease diagnosis and initiating treatment sooner translates to better patient outcomes more often than not. The field of diagnostics is the yin to medical treatment’s yang. They

    Read More
    Public
  • Rex is on the rebound, expanding geographic reach with Delta Air Lines

    Airlines are examples of logistical excellence. There’s a mind boggling amount of operational planning cogs that need to turn to move people and their stuff to where it needs to go. Getting there on time and in one piece is one thing, maximising efficiencies for the airline is another.  In an effort to improve their

    Read More
    Public
  • “Scars are more than skin deep”: Why Professor Fiona Wood is working with this biotech to melt away scars

    The skin is one of the most overlooked, complex and essential organs. It is the body’s first line of defence against dehydration, infection, and injury and plays a role in thermoregulation, vitamin D absorption and the nervous system.   Throughout the course of life we are bound to end up with scars from adventures and mishaps,

    Read More
    Public
  • Botanix receives supportive FDA designation for antimicrobial gel

    Stamping the letters ‘FDA’ on a Company announcement is a surefire way to flag investors’ interest. Today it was clinical dermatology company, Botanix Pharmaceuticals’ (ASX: BOT) turn to wave the FDA flag following the granting of a new Qualified Infectious Disease Product designation for BTX 1801, an investigational antibacterial product.  Focussed on both dermatology and

    Read More
    Public
  • New trial results from Actinogen hold promise for Alzheimer’s treatment

    Most people experience some level of cognitive decline as they get older. It’s a cruel, albeit normal part of the ageing process. Losing agency, cognition and function to Alzheimer’s disease is far from normal, and affects 1 in 10 Australians over 65 years of age, and 1 in 3 over 85.  Whilst pharmacologics do exist

    Read More
    Public
  • Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch

    “How much does it hurt, on a scale of 1-10?” Easily the most frustratingly vague of medical questions due to the huge difference in pain thresholds and perceptions. I don’t know about you, but I’m saving my 10 for childbirth.  Nonetheless, when the answer falls beneath an epidural-requiring 10, many of us reach for simple

    Read More
    Public
  • This $22 million company is changing the future of surgery

    The first evidence of surgery, if you can call it that, dates back to the Neolithic and pre-Classical periods where skull trephining took place. The gruesome practice of cutting small holes in the head was thought to rid the body of spirits and was widely practised throughout Europe, Africa and South America. The Egyptians even

    Read More
    Public
  • TSN is effervescent, having inked two new deals for supply of ingredients to beverage companies

    Since undergoing a pivot in strategic direction The Sustainable Nutrition Group (ASX: TSN) is making headway in the growing hemp and plant-based products space.  The worldwide plant based food market is predicted to reach USD$162 billion by 2030. Australia is the third fastest growing vegan food market in the world with many companies adapting to

    Read More
    Public
  • PPK Group is saying Cu to those blue face masks

    PPK Group (ASX: PPK) has a lot of balls in the air. Like, A LOT. From mining to ballistic armour, lithium batteries and now face masks…(?) Yep, their foray into the COVID boosted medical supply market has paid off, with the Therapeutic Goods Administration (TGA) approving their antiviral, antibacterial face masks for use in Australia. 

    Read More
    Public
  • Bigger fish: ResApp to be acquired by pharma giant Pfizer

    It’s not a question of AstraZeneca or Pfizer for digital health company ResApp Health (ASX: RAP) who have today entered into a binding scheme implementation deed to be acquired by pharmaceutical giant, Pfizer. Yes, one of the world’s biggest pharma companies has been perusing the ASX for a small homegrown biotech to snap up, we’re

    Read More
    Public
  • High Court sides with AFT Pharmaceuticals after Nurofen maker dispute

    Sticks and stones may break my bones but words may result in legal action because they can be misconstrued despite conscious wording.  Luckily for AFT Pharmaceuticals (ASX: AFP) the Australian High Court has sided with them, dismissing complaints made by the makers of Nurofen, Reckitt-Benckiser around the advertising of AFT’s painkiller product, Maxigesic.  Just yesterday

    Read More
    Public
  • Ardent Leisure Group set to cash in on US arcades business and turn focus to theme parks

    After several years of M&A interest in their US arcades business, Ardent Leisure Group (ASX: ALG) is set to offload their Main Event business to US operator Dave & Buster’s for USD $835 million on a cash and debt free basis.  The Group, alongside co-owner RedBird Capital Partners, is selling retail entertainment business Main Event

    Read More
    Public
  • Rhythm Biosciences’ new clinical trial shows increases accuracy for their simple cancer blood test

    Colorectal cancer is the second leading cause of cancer-related death in Australia. This can be attributed to the silent nature of the disease, not causing symptoms until tumours are well established.  The Australian Government is all too aware of this, having created the National Bowel Cancer Screening Program with the goal of early detection to

    Read More
    Public
  • ResApp signs pilot which will see their tech used in 4 major UK hospitals

    There isn’t much your smartphone can’t do. The power we have in our pockets is sometimes mind blowing. Amongst the torch function, Candy Crush and your banking app, you may begin to find more health tracking, medical based apps thanks to companies like ResApp Health (ASX: RAP). ResApp is busy developing smartphone applications for the

    Read More
    Public
  • WA based meal kit company partners with Thermomix, an appliance owned by half a million Australians

    In the age of convenience, shopping trips are becoming obsolete. As if click and collect, direct to your boot wasn’t convenient enough, many Aussies are now opting for meal kits, delivered directly to their front door.  The global meal kit industry experienced a serious boom during the height of the COVID-19 pandemic when people were

    Read More
    Public
  • Gratifii’s customer loyalty tech reaches over 800 restaurants globally

    Since emerging from lockdown and COVID restrictions, the world has been busy catching up with friends and filling social calendars with coffees, dinners and drinks.  Full social calendars have meant full venues, with vendors breathing a collective sigh of relief now that things are pretty much back to normal. Enterprise loyalty and rewards business Gratifii

    Read More
    Public
  • Nyrada drug offers potential world first oral treatment for concussion

    Rummage through any garage and chances are you’ll find a can of WD40. The name arose after 39 failed attempts at creating the trademark degreaser. You know what they say, 40th time’s a charm.  In the pharmaceutical arena, failures, tweaks and fine-tuning are par for the course. Preclinical stage drug development company Nyrada (ASX: NYR)

    Read More
    Public
  • We wade through this radiopharmaceutical company’s news so you don’t have to

    Seeing ‘Cu-64 SAR-bisPSMA’ in the title of an ASX announcement is enough to make many keep scrolling. However, clued in investors who read on and plug ‘radiopharmaceuticals’ into their search bar will uncover the massive market value of the space and its transformative potential. Clinical stage radiopharmaceutical company Clarity Pharmaceuticals (ASX: CU6) is an oncologyRead More
    Public
  • Predictive test for diabetic kidney disease receives new patent

    12% of global health expenditure is spent on diabetes. That equates to approximately USD $673 billion. Scarily, 1 in 2 adults with diabetes is undiagnosed.  Diabetic kidney disease (DKD) is directly caused by diabetes, and the damage the disease does to the kidneys. It is estimated that 1 in 3 diabetics will go on to

    Read More
    Public
  • Domino’s opens 900th store as more Japanese crave cheese pulls and carbs

    Starbucks never really took off in Australia. We just couldn’t get behind the sickly sweet, whipped cream covered combos that our American friends love so much. Starbucks quickly realised that our local coffee was way too good to even compete with, ultimately leading to the chain closing 61 stores in 2008 with a $143 million

    Read More
    Public
  • Noxopharm receives FDA designation for chemotherapy piggyback drug

    Noxopharm (ASX: NOX) will hopefully see an increase in value of their flagship drug following this morning’s announcement. The Company has been granted Orphan Drug Designation from the United States FDA for their proprietary drug, Veyonda, for the treatment of soft tissue sarcoma.  Orphan Drug Designation is given to certain drugs and biologics that show promise

    Read More
    Public
  • Can fish oil make your baby smarter? Clover Corp trials could hold the answer

    Babies born before 37 weeks of pregnancy are considered premature, and often are at risk of getting sick or suffering developmental issues. Multiple studies have confirmed that there is an interplay between prematurity and childrens’ intelligence quotient (IQ). Premature babies often have lower IQs than their full term peers.  To help premature babies reach their

    Read More
    Public
  • 4DMedical to compete with fairy bread for best Aussie invention

    Australians are a smart bunch. Although the pavlova is disputed, we gladly claim awesome inventions like the black box flight recorder, spray-on skin, the cochlear implant, plastic money and fairy bread (arguably the greatest invention of them all). Whilst I’m not sure much could compete with fairy bread, 4DMedical (ASX: 4DX) are giving it a

    Read More
    Public
  • International expansion as more hospitals register for Pharmaxis’ cancer treatment trials

    Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,

    Read More
    Public
  • Apps, not apples: NZ health food and smoothie bar seeks Plexure to develop new software and app

    Popular New Zealand based juice and smoothie bar, TANK is looking to enhance the digital experience for their customers. Understanding that their expertise lies in apples and not apps, TANK has engaged software tech company Plexure (ASX: PX1) to design and create a proprietary software platform for their stores.  The package will include a completely

    Read More
    Public
  • Digital payments is taking a new direction accelerated by eCommerce

    Remember the days of credit card signatures? Yeah, neither did I until I came across a 2014 (!) article whilst researching the state of POS terminals in 2022. It’s looking like those terminals may be going the way of the humble credit card signature, and even the magnetic strip thanks to ‘pandemic trends’ that have

    Read More
    Public
  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial

    Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has now announced the initiation of new clinical trials  in collaboration with global pharmaceutical company, Merck & Co (NYSE: MRK). The USD $46 billion company will support Imugene in evaluating the efficacy and safety of HER-Vaxx

    Read More
    Public
  • Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder

    The complexity of the human body never ceases to amaze me. So many systems need to work together to carry out seemingly simple tasks like walking, breathing and digesting. This complexity means that from time to time the convoluted web of neurons, strands of DNA and woven matrices of bone can be subject to defects. 

    Read More
    Public
  • Live Verdure keen to tap into the beauty market with hemp based skincare line in development

    The Australian skin care products market is forecast to reach over $300 million by 2025.  That’s a lot of moisturiser… And plant based nutraceutical and skin care company Live Verdure (ASX: LV1) is keen to cash in.  The Company’s hemp based “8 Seeds” skincare brand has had a face-lift with a reformulation for their multiple

    Read More
    Public
  • International Women’s Day shines spotlight on financial independence trends

    Social media has been abuzz with tributes and acknowledgements to women for International Women’s Day. It shows us just how far we’ve come, and how far we have to go.  One area where women lag is finance. On a global average we earn 23% less than men for the same work. The gender pay gapRead More
    Public
  • Silver linings of conflict, defence companies gain momentum

    I’m not sure about you, but I’m getting a bit sick of living in a VERY interesting part of next century’s history textbooks.  In recent weeks our newsfeeds have been swamped with horrifying images of the war in Ukraine which seems to be touching everyone in some way. Whilst the outpouring of support for those

    Read More
    Public
  • Out-the-box thinkers are just what the myelofibrosis treatment market needs

    The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that we may soon find resolutions to the complicated medical challenges of today.  The competitive nature of the space means that whoever is first to market has a clear advantage. Clinical stage pharmaceutical company Pharmaxis (ASX:

    Read More
    Public
  • Here’s how Bio-Gene is keeping your muesli bug free

    The range of creepy crawlies that find their way into Australian grain stores is broad enough to make you rethink your morning oats. I mean, no one likes the taste of flour beetles or weevils in their brekkie. Agricultural technology development company Bio-Gene Technology (ASX: BGT) agrees, and are working on solutions to common pests

    Read More
    Public
  • Spray On Skin available to over 200,000 more US healthcare providers following purchasing agreement

    4,440 US hospitals and health systems will soon have access to Avita Medical’s (ASX: AVH) proprietary RECELL System thanks to a purchasing agreement signed with Premier, a leading healthcare improvement company in the US.  Premier’s mission is to enable optimal patient care at reasonable cost within their alliance of 4,400 US hospitals and 225,000 other

    Read More
    Public
  • CardieX is making smart watches smarter

    I feel naked without my smart watch. I’m honestly addicted to getting my 10k steps and the little dopamine hit I get when my wrist buzzes, telling me I’ve hit a goal.  In awesome news for the health tech obsessed, smart watches are getting smarter.  Leading global consumer electronics developer, Mobvoi has launched the TicWatch

    Read More
    Public
  • Catapulting sports into the 21st century: How one company is using data to give teams an edge

    We all know that one guy who is downright obsessed with a certain sporting team, or player. The degree to which us humans can immerse ourselves in extraordinary feats of athleticism is astonishing (especially so when they catch you on your lunch break…). From the first team polo matches in Persia 2,500 years ago to

    Read More
    Public
  • Lumos Diagnostics receives regulatory approval for rapid test in Brazil

    Rapid antigen tests (or lack thereof) have dominated the headlines for months now. Turning your kitchen counter into a mini pathology lab is now an essential ritual in determining if it’s the sniffles or the dreaded ‘c word’.  Specialists in rapid point-of-care diagnostic technologies, Lumos Diagnostics (ASX: LDX) have been working on a useful test,

    Read More
    Public
  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products

    Us humans are in the near constant pursuit of ever increasing efficaciousness, especially in the field of medicine. How can we harness the best possible patient outcome in the least amount of time?  Theranostics is a field of medicine combining both therapeutics and diagnostic measures to tackle the most complex medical burdens of today.  Since

    Read More
    Public
  • Mad Paws becoming the ‘go-to’ for pet products and services with their latest acquisition

    I don’t do much without my little brindle side kick. She comes to the office, on dates, and Bunnings runs. I always order her a side of bacon on brunch outings and she frequently enjoys some cheeky nuggets when we find ourselves at a Maccas drive through. She exemplifies ‘man’s best friend’.  Unsurprisingly many Australians

    Read More
    Public
  • The ASX listed whisky company actually making whisky this week

    One ASX listed whisky company is pulling a lot of attention this week thanks to a certain CEO, and not for his drinking habits.  The Bainbridge ice saga provides a near perfect backdrop for Top Shelf International Holdings (ASX: TSI) to announce their latest deal with Coles Liquor Group.  NED Australian Whisky and Grainshaker Hand

    Read More
    Public
  • Bod seeks to register its cannabis extract as food in the UK

    Cannabis is having a major moment these past few years, trending in research and trickling down into the retail sector.  Medicinal cannabis company Bod Australia (ASX: BOD) has been selling cannabidiol (CBD) food products within the UK for a while now, however recent legislative changes around the substance dictate that manufacturers now require approval to

    Read More
    Public
  • Latitude to acquire Humm’s consumer lending division as BNPL cools off

    It’s confirmed- and whilst it doesn’t have the same scoop-your-jaw-off-the-floor effect as Afterpay’s (ASX: APT) $39 billion takeover from Square, Aussie grown BNPL Humm’s (ASX:HUM) consumer lending division is being acquired by Latitude Group (ASX: LFS).  The deal is expected to bring $55 million in annual synergies for Latitude which are anticipated to be fully

    Read More
    Public
  • MSL Solutions enjoys healthy revenue and pipeline opportunities in post lockdown world

    I’m not sure about you, but these past few months my social calendar has been FULL.  The lifting of lockdowns and the easing of restrictions meant that Friday night margaritas were back on, as were Saturday brunch sessions. My cup is full, and I’m loving the unrestricted access to my favourite humans and Melbourne’s many

    Read More
    Public
  • Vets a key part of the solution in restoring the racing industry’s image

    The racing industry gets a bad wrap in the court of public opinion. Some industry norms and practices are in desperate need of reform. Recent media exposes like the ABC report shone a light on the industry, including its broken aspects, prompting many Australians to question whether or not the thoroughbred racing industry is evenRead More
    Public
  • The funs of chemistry: How this pharma company is tapping into lucrative waste management

    Ever wondered how renewable fuel is made? Or how biodegradable plastics are created? There’s a lot that happens after you throw something away, and the process of repurposing materials is more complex than you might think. Clinical stage oncology company PharmAust (ASX: PAA) has an interesting subsidiary involved in just that. Epichem is a leading

    Read More
    Public
  • Not if, but when: expansion on the horizon for Digital Wine Ventures

    I recently gave a new name to the weekly soiree my friends and I conduct. It’s called “The Wine and Whine” (I should copyright that). The W&W is a safe space, often on my couch, where we crack open a bottle of Pinot Noir and whine about anything, from the state of the world, global

    Read More
    Public
  • Clinuvel to commence DNA repair drug clinical trials as new skin cancer treatment

    Sunbaking is a certified Australian pastime, so it comes as no surprise that we have the highest melanoma rate in the world.  Any lamington-eating, Waltzing Matilda-singing Aussie knows that skin checks are an important part of preventative healthcare, and that our unfortunate position in relation to the inconvenient hole in our ozone layer means that

    Read More
    Public
  • Adherium has begun manufacturing of their FDA approved respiratory inhaler

    5-10% of the world’s population suffer from asthma. That’s over 23 million people, 7 million of whom are children.  Whilst for some it is a minor nuisance, asthma can be a chronic and often debilitating problem and can be a precursor to numerous comorbidities. The condition causes the airways to narrow and potentially produce more

    Read More
    Public
  • Counter drone security tech company could make it big in Texas

    As drone technology continues developing at an impressive pace, so too is counter drone technology. Leaders in the field of drone threat protection DroneShield (ASX: DRO) provide artificial intelligence powered anti-drone solutions for a variety of sectors including defense, law enforcement, corporations, infrastructure and airports. Using a three tiered approach, their artificial intelligence- based tech

    Read More
    Public
  • Biome has a new probiotic approach to acne

    I had near perfect skin all throughout my teenage years, proclaiming boastfully to my blemish covered peers that “I dunno, I just skipped that phase.” I did not skip that phase. It just came later in life. Ugh. COVID related stress, mask wearing and the general travails of being a real adult brought about that

    Read More
    Public
  • Alloggio makes attractive acquisition in Magnetic Island

    Whoever named it Magnetic Island knew what was up. The pull of the equatorial paradise attracts over 290,000 people to the island every year. Short term rental property management company Alloggio (ASX: ALO) has made inroads on the island, today announcing the acquisition of Magnetic Island’s top holiday accommodation provider, Best of Magnetic. For a

    Read More
    Public
  • Luxury online retailer Cettire to jump on multi billion opportunity entering Chinese market

    Despite living in track pants for the majority of the last few years, the retail fashion industry is very much thriving. Now that we have dusted off the proverbial cobwebs from the nicer side of our wardrobes, global luxury online retailer Cettire (ASX:CTT) is expanding. With Mainland China set to become the world’s largest market

    Read More
    Public
  • Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test

    Your Friday crash course: Diagnostic biomarkers are in essence, used to determine whether or not a patient has a medical condition. Biomarkers can be molecular, histologic, radiographic and physiological, examples include heart rate, BMI and x-ray findings. Proteomics International Laboratories (ASX: PIQ) is taking molecular biomarkers to a whole new level, utilising proprietary biomarkers to

    Read More
    Public
  • Pharmaxis reports progress in clinical trials despite COVID affecting industry

    Things are well and truly on track for clinical stage pharmaceutical company Pharmaxis (ASX: PXS), a sentiment confirmed by CEO Gary Phillips in his shareholder address in their recent quarterly results. The Company has made significant progress in three clinical trial programs, with plenty on the horizon for their preclinical pipeline too.  Lead asset PXS-5505

    Read More
    Public
  • Meet the company behind contactless ordering for your coffee and cocktails

    QR codes are having a major moment and I’m definitely not complaining. You’d be lying if you said you don’t enjoy the convenience of being able to order food and drinks to the table, from your phone. No interruptions to conversation, no waiters getting your order wrong, no weird judgemental faces when you reiterate for

    Read More
    Public
  • Grow Daily, Grow Quarterly- Nutritional Growth Solutions living up to their name

    Global paedeatric nutrition company Nutritional Growth Solutions (ASX: NGS) are doing just that- growing. The Company creates a proprietary line of supplements scientifically formulated to enhance and support growth in children that has expanded significantly both in range and distribution locales. The clinically proven supplement range was formulated based on research into paediatric nutrition at

    Read More
    Public
  • Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug

    In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline.  For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the

    Read More
    Public
  • Clinical Pilates: The value add clinical exercise service at physiotherapy clinics growing in popularity

    It’s no secret that movement is the key to being a healthy individual. Clinical Pilates is one of the more productive ways of moving that might not get your heart rate up as much as that hardcore HIIT class but will deliver countless benefits when it comes to posture, movement, strength and flexibility. The original

    Read More
    Public
  • Imugene secures patent for new cancer vaccine in major oncology market

    Cancer treatment is slowly shifting away from the standard chemo and radiation and more towards immunotherapy as an alternative treatment. Unlike chemotherapy which destroys healthy, rapidly dividing cells in the body, immunotherapy is more targeted, using the patient’s own immune system to fight cancer. Chemotherapy’s attack on healthy cells causes the well known side effects

    Read More
    Public
  • ASX newcomer Alloggio expands further into Noosa accommodation market

    Having just come back from a week in Noosa I can totally understand accommodation provider Alloggio’s (ASX: ALO) decision to expand into the Sunshine Coast.  The bustling beachside locale is as close to paradise as you can get, boasting something for everyone with their vast array of shops, restaurants, beautiful beaches, surfing spots and walking

    Read More
    Public
  • The Food Revolution Group wants to revolutionise your morning smoothie

    Since being inaugurated into the world of full time work my mornings have become increasingly frantic. There’s only so much you can fit in before 9 and after 5 whilst getting adequate rest, exercise and maintaining some semblance of a social life… Eating well sometimes falls to the bottom of the list in favour of

    Read More
    Public
  • Contact lenses to slow nearsightedness to get further clinical validation in new trial

    In a break from news about contact tracing, I bring you some about contact lenses.  Nearsightedness is a very common condition where sufferers can see objects close to them clearly, but struggle with objects further away. The cause of this lies in the shape of the eye causing light rays to bend incorrectly and therefore

    Read More
    Public
  • HeraMED rolls out new maternal tech in major WA hospital

    Whilst the Government might be making (and subsequently reneging on) policy around prenatal care and IVF visits due to COVID, one company is actually making positive strides ahead.  Medical data and technology company HeraMED (ASX: HMD) is readying themselves for a full commercial rollout of HeraCARE, their prenatal and foetal health monitoring system to expectant

    Read More
    Public
  • Why you need to visit this Fremantle cargo shed turned brewery

    One 1926 cargo shed on the bustling Fremantle Harbour got a facelift recently, having been transformed into Good Drinks Australia’s (ASX: GDA) newest venue.  Good Drinks Australia is a passionate independent brewer with brands under its belt such as Gage Roads Brew Co, Atomic Beer Project, Matso’s and San Miguel.  The flagship site, named Gage

    Read More
    Public
  • This company would definitely be in your dog’s portfolio

    If we focus on silver linings, the pandemic actually brought with it many good things. Think the pleasures of click and collect, the convenience of telehealth appointments and the digitisation of almost every business. Another positive born from the crappiness was the rise in pet ownership, as people found themselves home more and in need

    Read More
    Public
  • Pulling art from the canvas and onto face masks: How Redbubble is faring

    Redbubble (ASX: RBL) has been helping artists transpose their art from the canvas and onto travel mugs, t-shirts and socks since 2006.  Today, Redbubble is a thriving online marketplace, complete with the modern day addition of face masks… how 2020. Accelerated growth in online spending throughout the pandemic, including faux-lockdowns caused by the latest Omicron

    Read More
    Public
  • Momentum continues for Pharmaxis with $1.4m in grants following oversubscribed raise

    Just days after closing their oversubscribed $9.8 million capital raise, drug developer Pharmaxis (ASX: PXS) has seen further funding devoted to its projects, this time from the Government to apply work towards skin diseases and pancreatic cancer.  The NMHRC Drug Development Grant scheme is an Australian government initiative set up to provide financial aid to

    Read More
    Public
  • Wide Open Agriculture continues Asian expansion with new distribution partner appointed

    The people of Hong Kong and Macau are set to receive yet another non-dairy alternative when it comes to their morning latte or bubble tea.  Wide Open Agriculture (ASX: WOA) has signed a distribution agreement with Metro Alliance Ltd. to distribute their carbon-neutral, regenerative oat milk through the region. Metro will also complete sales, marketing

    Read More
    Public
  • Investing over pancakes: this one app is a millennial essential

    Just the other day I was stupefied by the fact that my otherwise financially savvy boyfriend didn’t have Raiz (ASX: RZI) on his phone.  “YOU DON’T KNOW ABOUT RAIZ?!” I blurted out, mouth full of pancakes that he’d made (side note: this one is definitely a keeper).  “Who doesn’t know about Raiz? Give me your

    Read More
    Public
  • Uh oh…People: A new approach to treating Social Anxiety Disorder

    If the festive season has left you feeling depleted and ready for a solid few nights in, cemented to the couch, you’re not alone. Social interactions can be draining at the best of times for my fellow introverts, but it’s even tougher for those with Social Anxiety Disorder.  According to the Diagnostic and Statistical Manual

    Read More
    Public
  • Why haven’t we cured cancer yet?

    As investors, we are all looking to get in on the ground floor of a fantastic stock both for returns and maybe, gloating rights to our friends. Some of the best performing stocks are in the healthcare and biotechnology sectors with industry stocks making up 7% of ASX200 companies.  With many target diseases and conditions,

    Read More
    Public
  • Tackling the mental health crisis plaguing the veterinary profession

    The veterinary profession is in a state of flux. Whilst highly rewarding, the high-pressure demands of the job are testing, and often associated with a high risk of poor mental health. With increased society wide focus on mental health and wellbeing in recent years, awareness of what vets go through behind closed doors is onRead More
    Public
  • Creating a culture of wellbeing to become an employer of choice

    Whilst they might have just been acquired by fintech giant HUB24 (ASX: HUB) things haven’t changed at Class (ASX: CL1) with regard to their people and culture.  Investing in people has always been a priority for the tech company, especially given the so called ‘war on talent’ that has hiring managers and HR staff pulling

    Read More
    Public
  • Special delivery: unique drug delivery system receives new US patent

    Let’s rewind to Year 10 biology- you know that mitochondria is the powerhouse of the cell, chances are you vaguely remember the golgi apparatus but do you remember what an exosome is? Exosomes, or extracellular vesicles are little packages delivering molecules and enhancing cell-to-cell communication. Clinical- stage biopharmaceutical company Exopharm (ASX: EX1) is utilising exosomes

    Read More
    Public
  • Stuck in line waiting for a COVID test? This company is loving the 4+ hour wait times

    Perhaps the displeasure of waiting in line for hours to get a COVID test this holiday season would be slightly allayed if you were a shareholder in a pathology company doing the leg work? Investors who saw the value in pathology and ‘pro-pandemic’ stocks like Australian Clinical Labs (ASX: ACL) will be glad to read

    Read More
    Public
  • Concussion tech company bringing product to grassroots athletes

    Take it from me- concussions are awful. There’s unrelenting dizziness, nausea and that foggy brain feeling, if you’re lucky. Those who fare worse can be left with permanent issues with balance, mood, memory and cognition.  A major cause of concussion is sport, where concussion management technology company HITIQ (ASX: HIQ) is working to reduce its

    Read More
    Public
  • Treasury Wine Estates has a new, sustainable focus on viticulture

    Sustainability and environmentalism are important in every aspect of our lives, and every effort counts. Businesses that are environmentally conscious fare better than their counterparts in multiple areas from reduced overheads to appealing to a larger client and talent base. Corporate strategies are being designed with sustainability in mind to ensure longevity and reduce the

    Read More
    Public
  • Travel tech platform Alloggio to expand into Great Ocean Road region

    Despite omicron related fears looming, travel tech company Alloggio (ASX: ALO) made their ASX debut this month with a $45 million float.  The vacation accommodation platform chose to go ahead with their IPO just in time for the holiday season where more Australians are likely to ‘holiday at home’, rediscovering domestic offerings.  With their share

    Read More
    Public
  • Newly rebranded xReality Group’s military VR business division progresses

    Having just undergone a full rebrand to match their new business direction, xReality Group (formerly ISA Group), now trading under the ticker code ASX: XRG, are making headway in their Defence focused business division. The refocused Company released a market update on the Operator Tactical Solutions business unit which creates virtual reality products for training

    Read More
    Public
  • Viva expands fitness studio portfolio with new low cost membership brand

    There are few things that feel as fantastic as the buzz through your body after a good Vinyaya sesh where a skilled yoga instructor has conned you into a full body workout under the guise of a ‘restorative’ yoga practice. For you non-yogis out there, I implore you to try it for yourself. It’s mildly

    Read More
    Public
  • Instant PayDay lending: will wage advance apps be the next fintech craze?

    There’s a new player in the fintech lending space, with a tongue-in-cheek name that is no doubt a brazen dig at the prolific Afterpay (ASX: APT).  I’m talking about Beforepay, the platform that lets you access your wages early, for a set fee. Less: buy now, pay later. More: wage advance, buy now, with fees…not

    Read More
    Public
  • Hipages just acquired this business… Their unfortunate name comes with stacks of market potential

    Despite a really unfortunate name, New Zealand online tradie marketplace “Builderscrack” has been acquired by hipages (ASX: HPG), Australia’s largest online tradie marketplace.  (I mean honestly, I can’t be the only one who thinks of a plumber’s butt peeking out of the top of jeans as he crouches under a sink when reading that website

    Read More
    Public
  • From bed linen to defense- material tech company Alexium enters new market

    Materials tech has come a long way. Think kevlar, lycra and foam- all complex textile materials that are integrated into everyday items.  The dynamic field of textile science encompasses fibers, dyes and production methods. The next generation of textile product innovation lies in phase change textiles. These contain materials that react immediately with changes in

    Read More
    Public
  • Why reinvent the wheel? Starpharma is using their tech to improve existing drugs

    We live in the age of optimisation. Constantly asking questions like how can we be more efficient? How can we streamline processes? How can we enhance ourselves with the resources available?  The pharmaceutical scene is no different, seeking to optimise drugs in any way possible to produce better patient outcomes.  Biopharmaceutical company Starpharma (ASX: SPL)

    Read More
    Public
  • New market wide open for Wide Open Agriculture’s carbon neutral oat milk

    Wide Open Agriculture (ASX: WOA) is vying for a top spot in the ever growing plant based milk section at your local supermarket with the expansion of their retail facing brand, Dirty Clean Food.  The Brand’s headline product is their ‘OatUP’ oat milk which is now going to be available to Middle East markets following

    Read More
    Public
  • Promising results emerge for HeraMED’s telehealth solution for antenatal care

    With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers. Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote

    Read More
    Public
  • PharmAust shrinks proprietary tablet for use in COVID-19 trials

    Good things come in small packages, like PharmAust’s (ASX: PAA) newest iteration of their monepantel (MPL) tablets.  The clinical stage biotechnology company has manufactured smaller versions of their lead asset, MPL, a potent small molecule drug that has been shown to affect key pathways associated with cancer and other diseases. PharmAust have studied MPL for

    Read More
    Public
  • Micro Investing app gets not-so-micro with $10m investment from Seven West Media

    Everyone’s favourite micro investing app is growing!  After their recent milestone of $1 billion in Funds Under Management, Raiz (ASX: RZI) is using that momentum to drive further growth, today announcing that a strategic investment has been made in the Company by Seven West Media (ASX: SWM). Australia’s largest diversified media business, Seven West Media

    Read More
    Public
  • Better than a sudoku: could this drug be the key to preventing Alzheimer’s?

    Our minds can be our greatest asset and our biggest enemy. The same humans that built aeroplanes, rockets and the internet are just as prone to ailments like depression, anxiety and functional cognitive decline. Unfortunately when it comes to cognition, doing the odd sudoku probably won’t cut it if you’re hoping to maintain your current

    Read More
    Public
  • Laying down new roots: Roots ag-tech expands into Africa

    Anyone who has tried to grow coriander on their apartment balcony (like me) will understand that food production, even that of a measly herb, is somewhat of an art form. The climate, topography and differences in soil all affect the type and quality of foods that can be grown in certain regions.  Adding to an

    Read More
    Public
  • Travel bouncing back: Webjet returns to profitability as borders reopen

    With the opening of borders just around the corner, Aussies are keenly booking trips to see friends, family or just another city. With the uptick in bookings, the travel industry is slowly but surely snapping back to resemble its pre-COVID self.  Travel booking behemoth Webjet (ASX: WEB) is glad to see demand growing again in

    Read More
    Public
  • Predictive tests: diagnosing disease before it arises

    We are all different. It’s what makes us unique. Companies are all too aware of this, with  experiences and products evolving to cater to personal needs and preferences. From mixing custom skin care formulations to Spotify music recommendations, personalised experiences are more memorable and valuable to the customer. The same goes for medicine. Personalisation means

    Read More
    Public
  • Industry wide recall means rough seas for seafood producers

    The seafood industry is in damage control mode after authorities issued an industry wide recall on products from the Coffin Bay oyster production zone following a rise in cases of food poisoning from products grown in the region.  The South Australian Department of Health and Wellbeing (DHW) and the Department of Primary Industries ordered all

    Read More
    Public
  • Everything happens for a riesling: Treasury Wines expands in the US with Napa Valley acquisition

    There are two non-negotiable beverages in my eyes: coffee and wine. At the end of the work day you will most likely find me firmly attached to the couch with a glass of red and a good book.  I have a feeling that the folks over at Treasury Wine Estates (ASX: TWE) are my type

    Read More
    Public
  • Viva Leisure deals increasingly more endorphins as lockdowns ease

    Not much compares to the endorphin kick you get after a great gym sesh. Yep, I don’t care what anyone else says, dragging yourself out of bed and into a gym to do endless burpees feels GOOD (when you’re done). Viva Leisure (ASX: VVA) is keen to become the endorphin dealer of choice for Aussies

    Read More
    Public
  • I just want (oat) milk that tastes like real milk

    When it comes to plant based milks, oat milk reigns supreme (in my opinion at least). However, I often spend far too long standing in the supermarket aisle on my weekly shop deciding which one to buy… Before inevitably picking a selection to sample. Despite what might seem like a near saturated market, alternative milks

    Read More
    Public
  • Australian Clinical Labs tips over 1000 collection sites with new acquisition

    Up 23% since their ASX debut in May earlier this year, Australian Clinical Labs (ASX: ACL) are expanding, with the acquisition of Medlab Pathology.  Medlab is a leading private pathology provider comprising two main laboratories and 288 collection sites across both NSW and QLD. The highly complementary acquisition will see ACL’s market share in NSW

    Read More
    Public
  • Plant-based proteins well worth investment for TSN as they seek to enter $10.8 billion market

    With plant based diets becoming increasingly mainstream vegan options are being offered almost everywhere, and the sports nutrition industry is no exception.  The recently rebranded Sustainable Nutrition Group (ASX: TSN) is entering the $10.8 billion global plant based- ingredients market through a new partnership with Australian Plant Proteins (APP) to develop a hemp based concentrate

    Read More
    Public
  • Hotel? Alloggio… Or SiteMinder: The two tech based travel stocks to watch

    Stepping out of a string of seemingly endless lockdowns into a COVID endemic world hasn’t deterred Aussies from jumping straight back into life as normal. With the holiday period looming people are keen as mustard to get the hell out of dodge and plonk themselves on a beach somewhere for some much needed R&R.  Qantas

    Read More
    Public
  • Raizing the bar: popular microinvesting platform surpasses $1 billion funds under management

    In the digital age it is easier than ever to invest. With the ability to purchase fractional interest in shares and ETF portfolios at our fingertips, it’s no surprise that platforms like Raiz (ASX: RZI) have skyrocketed to the top spots in app stores.  The popular microinvesting platform has just hit $1 billion in funds

    Read More
    Public
  • FDA gives green light to Pharmaxis drug trial in liver cancer where there’s a desperate need for new treatments

    Clinical stage drug development company, Pharmaxis (ASX: PXS) is making a name for themselves in the oncology sector, with their lead asset oncology drug yielding promising results in numerous studies.  PXS-5505, a drug designed for the treatment of rare blood cancer myelofibrosis is built on Pharmaxis’ proprietary platform, harnessing the power of enzyme inhibition to

    Read More
    Public
  • This is an article about dog poop

    Dogs will provide you with many things. One of those is a constant stream of poop.  Yep, smelly landmines will inevitably be yours to deal with if you choose to get a dog. Picking up poop on morning walks with my staffy is absolutely NOT the highlight of my day, nor will it ever be.

    Read More
    Public
  • The age of one-dimensional marketing is over, Motio is bringing digital advertising into real world settings

    Most advertising these days is predominantly digital and has infiltrated almost every platform we use. Sometimes however, it’s necessary to close the laptop and go out into the real world, but clever marketing minds have moved past the stagnant billboards and one-dimensional print ads of the Mad Men era, blurring the lines between the digital

    Read More
    Public
  • Brick by brick: Robotics construction company FBR secures work abroad

    Building is tenuous. The time consuming and resource heavy construction process is expensive and is long overdue for a shake up. In a world where automation regions supreme, West Australian robotics company FBR (ASX: FBR) is giving building a modern spin.  Their Hadrian X bricklaying robot builds structural walls efficiently, economically and sustainably compared to

    Read More
    Public
  • InhaleRx is the microcap making it possible to vape cannabis

    InhaleRx’s (ASX: IRX) name wasn’t the only thing that changed in their October rebrand. Previously LifeSpot Health, the Company overhauled their entire strategy, focus and branding, pivoting from a medicinal cannabis device company promoting skin cancer screening to inhaled prescription medicine delivery devices. Inhalation of medications is an efficient way to deliver drugs given the

    Read More
    Public
  • Applyflow making inroads to $15 billion recruitment industry

    With the way we work changing it’s only fitting that the way we find work changes too. Recruitment tech company Applyflow (ASX: AFW) is working to create seamless recruitment experiences with their software.  Designed to ‘reinvent recruitment’, the Applyflow platform combines recruitment sites, job boards, automations and applicant tracking into one system. The ultimate goal

    Read More
    Public
  • This little Aussie biotech just had their best quarter on record

    Clinical stage drug developers Pharmaxis (ASX: PXS) have had a busy quarter with two of their lead drug assets progressing through to the next stage of their clinical studies while sales of their existing products were up 395%. The Biotech’s cancer drug, PXS-5505 has progressed to a Phase 2a study in myelofibrosis patients following pleasing

    Read More
    Public
  • This natural medicine that acts like alcohol is gaining popularity

    Whilst medicinal cannabis might be all the rage currently, there is no shortage of other natural medicines. Kava is a plant native to the western Pacific islands and has been used in ceremonial drinks for centuries. The plant promotes relaxation thanks to kavapyrones, a substance that acts similar to alcohol in the brain, which has

    Read More
    Public
  • Ostreophiles, get your shucking knives ready- Angel Seafood increases stock by 94%

    Charles Dickens wrote “Poverty and oysters always seem to go together”.  Yep, oysters used to be a poor man’s food. A cheap source of protein often supplementary to beef.  Thanks to overharvesting in the 20th century the bivalves have since become a pricey delicacy, pulling profits for growers like Angel Seafood (ASX: AS1), the Southern

    Read More
    Public
  • Get on the 78 Degrees Gin: Mighty Craft brings acquisition home

    Punctilious Melbournians followed the Premier’s advice to ‘get on the beers’ this weekend, with bars brimming and post-lockdown festivities spilling out onto the streets. The city was abuzz with reunions and smiles, washed down with spritzes and lagers.  A seemingly well timed announcement by beverage company Mighty Craft (ASX: MCL) this morning details more opportunities

    Read More
    Public
  • Out of the holding pattern: Aussie planes return to the sky after two years of lockdown

    All headlines this morning will be about the lifting of lockdown, and this one will be no different. After a mind numbingly high number of days stuck indoors experiencing groundhog day it’s finally time to hit the hairdresser, the pub, and hug our loved ones.  Coming out of this extraordinary period in history has had

    Read More
    Public
  • Rhythm Biosciences’ colorectal cancer test outperforms the current gold standard, to hit market in 2022

    Despite a robust national cancer screening program, colorectal cancer remains the second most common cause of cancer death (after lung cancer) in Australia. Under the National Bowel Cancer Screening Program, Australians are invited to complete a faecal occult blood test to screen for the disease every two years from the age of 50-74. Evidence shows

    Read More
    Public
  • Whispir to scale globally with rising headcount following vaccination communications success

    In an age where we are bombarded with communications, companies need to stand out from the crowd. With an ever growing list of channels to connect through, companies need to adapt their messaging without compromising on clarity.  Enter Whispir (ASX: WSP), a global SaaS company providing communication solutions through their workflow platform. The Company expands

    Read More
    Public
  • Digital employee wellness platform experiences growth despite dwindling cash receipts

    Employee wellness has been at the forefront of employer’s minds since the pandemic pulled us out of the office and left us as tracksuit clad, makeup free recluses. At least in my case anyway.  Digital employee wellness company Limeade (ASX: LME) has seen organisation wide growth indicated by their increase in headcount and operating cash

    Read More
    Public
  • Can this biotech tap into a $183 billion market by buying time for stroke patients?

    Shareholders who took a punt on Argenica Therapeutics (ASX: AGN) when they made their market debut earlier this year will be pleased to read the Company’s roadmap to Phase 1 clinical trials.  The recently-listed Company has been subjected to the trials and tribulations of being listed, with a sharp sell-down post-IPO leaving their share price

    Read More
    Public
  • The meteoric rise of the meal kit thanks to a pandemic and a convenience economy

    The magic of click and collect and home delivered meal kits was around long before COVID-19 however, the pandemic has served as an undeniable accelerator to companies like My Food Bag (ASX:MFB), a New Zealand based meal kit delivery company. The Company creates and delivers meal kits with 98% NZ ingredients and simple recipe cards

    Read More
    Public
  • Resonating with investors – digital health company looking to turn themselves around

    Following months of a steadily downtrending share price, things seem to be looking up for digital health company Resonance Health (ASX: RHT).  Specialists in noninvasive medical imaging, the Company creates devices and software to aid in diagnosis and improve patient outcomes.  Having received regulatory approval in the USA, Europe and Australia, Resonance’s products are already

    Read More
    Public
  • Dosing commenced in Phase 2 trial for Pharmaxis’ lead asset myelofibrosis drug

    With a share price that has effectively doubled over the past few months and a drug pipeline beginning to snowball its successes, investors that identified Pharmaxis (ASX: PXS) early on are justifiably ecstatic. The clinical stage drug developers have had a strong start to FY22 with their lead asset, oncology drug PXS-5505 and anti-skin scarring

    Read More
    Public
  • Goodbye lounge room gym! Viva Leisure expands portfolio just in time for lockdown lift

    If you’re like me you’re probably a bit over using your lounge room as an office, cinema, dining room and gym. The multidisciplinary heart of my home is often littered with dumbbells, yoga mats, wine glasses and whatever book I’m currently reading. It’s an odd picture.  The thought of getting back into a real gym,

    Read More
    Public
  • ResApp expands their diagnostic offering into disease affecting 1 billion worldwide

    Experts estimate that sleep apnoea affects nearly 1 billion people worldwide. Every year, 4 million people die prematurely from chronic respiratory diseases such as COPD, asthma, acute respiratory tract infections, tuberculosis and lung cancer.  The global impact of respiratory based ailments is expansive, prompting The World Health Organisation to launch the Global Alliance Against Respiratory

    Read More
    Public
  • Contraceptive alternatives – Mayne Pharma receives FDA response putting them a step closer to approval

    Of the myriad of contraceptives out there, those that don’t require daily effort are gaining in popularity. As our lives get busier and brains get fuller, women are electing for long term, ‘set and forget’ birth control measures. Two thirds of Australian women of reproductive age use birth control. Whilst methods like the oral contraceptive

    Read More
    Public
  • Race Oncology gains more patents for their cancer drug, Zantrene

    The field of cancer research is certainly buzzing with key research yielding new medications with the ultimate goal of improving patient outcomes.  The mind numbingly broad list of diseases and disease subtypes that fall under the ‘cancer’ banner might make it seem like little to no progress is being made in conquering cancer. Look a

    Read More
    Public
  • Revolutionary cancer drug approved to commence Phase 2 clinical trials

    Clinical stage drug development company Pharmaxis (ASX: PXS) is one step closer to seeing their revolutionary cancer drug reach commercialisation. PXS-5505, the Company’s lead asset has received the go-ahead from the safety committee to begin Phase 2 trials following positive results from the Phase 1c study which saw patients with myelofibrosis treated for 28 days

    Read More
    Public
  • Could the milkman make a comeback? A case for reusables in food packaging

    Admittedly, the days of the milk man visiting, clanging glass bottles were well before my time. That being said, there’s something so wholesome and quaint about freshly delivered milk and bread in the morning. For those of a similar vintage to myself, here’s what would happen- the night prior to your milk delivery you’d leave

    Read More
    Public
  • Nest feathering Aussies propel Nick Scali to acquire Plush after strong pandemic earnings

    Cocktails are out, couches are in. Having become a mainstay of Saturday night lockdown plans, many Aussies have opted to upgrade their couch (and living room furniture), a trend serving to benefit furniture and homeware retailers. The niche market has reaped the rewards of Aussies feathering their nests in an effort to turn their space

    Read More
    Public
  • Prioritising employee wellness, how this fintech is making R&R the new R&D

    Organisational and personal development opportunities have largely fallen by the wayside for companies since the pandemic forced workers out of the office and into pyjama pants.  Logistical and technological barriers mean that it isn’t as easy as getting everyone into a room together for scheduled development programs, despite being an important part of business growth. 

    Read More
    Public
  • Chrome or Edge? Mac or Windows? Afterpay or Zip?

    The best tech often has a rival, another company doing similar work. Healthy competition puts consumers in prime position as companies battle it out to sweeten the deal and get you to hand over your precious cash.  iPhone people and Android people are almost two different social subclasses. So are sleek Mac users and practical

    Read More
    Public
  • Why this human dermatology company is now looking into treatments for dogs

    Pets are family. The staffy cross under my desk who lives here rent free will attest to that. Our fur children are exactly that, children. With little personalities, quirks, likes and dislikes it’s hard not to think of the four legged friend you share your space with as more than a dog.  Numerous studies have

    Read More
    Public
  • How to diversify your share portfolio

    “Don’t put all your eggs in one basket”. The simplest analogy and central thesis for why you should diversify your share portfolio, rewritten countless times in articles on the topic. You already know that investing is the key to building long term wealth. Establishing an investing strategy is important to help get you there; however,

    Read More
    Public
  • Body of evidence grows for Cynata’s stem cell production platform

    “Published” is an accolade that many scientists strive for. Showcasing your work and communicating your results to peers feels good, regardless of age.  The setting of scientific show and tell is within scientific journals, offering an enduring record of a scientist’s findings and impact on the world (vastly less obtrusive than being sat down and

    Read More
    Public
  • Has this medtech company created a new vital sign?

    Vital signs are important indicators of health, however, they often don’t show the whole picture. Technological advancements in the medtech world are equipping clinicians with valuable, detailed insights into their patients’ health, assisting with clinical decision making and optimising patient outcomes.  With over 700 devices in clinical use worldwide, Impedimed’s (ASX: IPD) clinically validated, fully

    Read More
    Public
  • Patent granted, share price up: Archer Materials reaches significant milestone

    Shareholders will be pleased to read that Archer Materials (ASX: AXE) has been granted a US patent for their 12CQ quantum computer chip.  The highly anticipated announcement comes after a media fumble last month that saw a popular Australian financial news masthead report several inaccuracies, prompting the Company to respond with a curt market release. 

    Read More
    Public
  • Top cosmetic dermatologist endorses Zelira’s cannabis-based acne treatment

    In 1964 Israeli chemist Raphael Mcechoulam boarded a bus to the Weitzman Institute in Rehovot with 5 kilos of hashish he received from the Israeli police. He used the material to isolate and identify THC, the psychoactive compound in cannabis. The discovery saw him crowned as “the father of cannabis research”.  Cannabinoid medicine specialist company

    Read More
    Public
  • Wellfully’s products expand into Russia, and my bathroom cupboard

    I am what my ex would call a ‘goop collector’.  This nickname was bestowed unto me due to my propensity to spend copious amounts of money on skincare products (goops), only to use half the bottle before finding something more exciting or more effective.  Honestly, looking at my bathroom cupboard makes me cringe at the

    Read More
    Public
  • Recognising the power of the female purse

    The ASX’s 2020 Investor Study details the lay of the land, revealing who is investing, when and how. The study reported that in the last two years there has been an influx of younger investors, approximately one quarter of recent new investors were between the ages of 18 and 24. The study also revealed that

    Read More
    Public
  • The OG OJ: Classic Aussie juice range gets a shake up

    Juice- both a Saturday morning staple and an adjunct to that near toxic tequila you got for your 18th.  Fruity beverage mogul Food Revolution Group (ASX: FOD) is helping keep those crappy tequila brands in the green with the expansion of their range of juices.  The Company plans to expand three products throughout the Coles

    Read More
    Public
  • This company turns bananas into sustainable food packaging

    With consumers becoming increasingly environmentally conscious, sustainable packaging is becoming the new norm.  Agricultural waste fibre technology company Papyrus Australia (ASX: PPY) has developed a zero-waste, chemical-free process of converting globally available agri-waste into usable products, thereby reducing the creation of methane and waste.  Where do they source this agri-waste? Bananas!  On average, one hectare

    Read More
    Public
  • EMVision is pioneering the next generation of stroke diagnosis

    It’s no secret that medical research and development is an expensive pursuit. Many medtech and pharmaceutical companies are constantly on the lookout for non dilutive funding to accelerate their projects, hopefully to market.  Medtech company EMVision (ASX: EMV) is focused on developing their portable medical imaging technology. The Company has secured access to $8 million

    Read More
    Public
  • Encouraging data for Orthocell biotech in pursuit of next gen ACL knee reconstructions

    The football player laying on the field clutching their leg might seem overdramatic until you read that the incidence of anterior cruciate ligament (ACL) tears is quite high – up to 10 injuries per 1,000 game hours, with the highest rates of injury reported in professional players.  Such an injury will sideline a player for

    Read More
    Public
  • Winning the war on talent: Setting the cultural standard for women in fintech

    Diversity and inclusivity in the workplace is increasingly important. More and more asset managers are looking at company environmental, social and governance (ESG) policies as a guidepost when making investment decisions. Both the technology and finance industries are among the least gender diverse. A recent study by Harvard Business Review revealed that only 30% ofRead More
    Public
  • Antimicrobial resistance at ‘tipping point’, threatening global food supply

    In a time where investors are more clued in than ever, environmental, social and corporate governance has become increasingly important. Whilst most companies simply check an ESG box, others go beyond and actively contribute to solving global challenges.  Last month the Global Leaders Group on Antimicrobial Resistance, an interagency group comprising experts from all overRead More
    Public
  • The medtech company looking to diagnose COVID by… sound…

    COVID-19 represents unchartered territory for everyone. Governments and various organisations across the globe have struggled to develop systems, policies and coordinate programs whilst researchers have scrambled to pull together clinically valid trials to deepen our understanding of our latest threat. ResApp (ASX: RAP) is a digital health company developing smartphone apps for both the diagnosis

    Read More
    Public
  • Acrux seeks FDA approval of generic acne treatment to disrupt $30 million market

    Mask-ne, iso skin, whatever the beauty blogs have dubbed it, acne sucks.  Yes, one of the many irritating side effects of this pesky pandemic is the resurgence of my teenage skin. Regular mask wearing and heightened stress has contributed to my new spotty appearance.  Sadly, my bathroom wouldn’t make for a very good “shelfie” these

    Read More
    Public
  • Pandemic presents opportunity for Aussie respiratory technology company

    I know, I know. We’re all sick of hearing news about the C word. Disgruntled Melbournians and aggrieved Sydneysiders aside, several companies are experiencing revenue boosting tailwinds from the pandemic situation. Respiratory technology company, Rhinomed (ASX: RNO) has received an initial purchase order from the Victorian Department of Health for one million Rhinoswabs to further

    Read More
    Public
  • FDA clearance received for yet another Adherium device

    Chronic respiratory disease is a growing concern, especially in the age of COVID-19, with a snowballing amount of studies examining the effects of ‘long COVID’- where symptoms persist long after the virus has cleared.  Medtech company Adherium (ASX: ADR) has what could be a very relevant and consequently very profitable suite of products designed to

    Read More
    Public
  • Digital healthtech 1st Group refreshes digital strategy to boost investor confidence

    Heeding the old adage “he who fails to plan, plans to fail”, digital health company 1st Group (ASX: 1ST) has shared their growth plans for FY22 with the market. With several brands already under their belt, the Company is building integrated platforms for online search and appointment booking services. Their flagship product, MyHealth1st is a

    Read More
    Public
  • Patents granted for Orthocell’s suture-less method of soft tissue repair

    The earliest known use of surgical sutures dates back to 3000 BC in ancient Egypt. Since then humans have experimented with sutures made from flax, cotton, hair, tendons, silk and anything vaguely thread-like. Taking surgical suturing to the next level is Orthocell (ASX: OCC), a Western Australian based company developing next-gen regenerative medicine products. The

    Read More
    Public
  • AnteoTech signs distribution rights in Turkey for their rapid COVID-19 test

    Companies the world over are pooling their strengths to address COVID-19, one of the most important global challenges of our time. Seeking to help in the field of rapid point of care testing, AnteoTech (ASX: ADO) is applying their proprietary technology to create the EuGeni COVID-19 Antigen Rapid Test.  The Company has signed a distribution

    Read More
    Public
  • How BCAL Diagnostics is improving minimally invasive methods of early cancer detection

    With 1 in 7 Australian women diagnosed with breast cancer, the demand for a minimally invasive, accurate diagnostic test is growing. Whilst health professionals recommend bi-annual breast screening for women aged 50-74, the invasive nature of imaging and ultrasound techniques leads to low compliance. There is well documented evidence that early cancer detection markedly improves

    Read More
    Public
  • Positive clinical trial results for nutritional shake bolsters $5m cap raise

    Days after raising $5 million via a capital raise to accelerate their global strategy, Nutritional Growth Solutions (ASX: NGS) has released clinical trial data showing positive results for their product Healthy Heights Grow Daily Boys 10+.  Just one of their growing range of products, Nutritional Growth Solutions creates clinically tested nutritional supplements for children, a

    Read More
    Public
  • 4DMedical’s clinical pilot program to progress following successful first phase

    Following a particularly well received first phase of their clinical pilot program, medical technology company 4DMedical (ASX: 4DX) is advancing their respiratory imaging platform to Phase 2 of their clinical pilot program. Conducted with Australia’s leading medical imaging provider, I-MED Radiology Network, Phase 1 of the program saw radiologists use 4DMedical’s proprietary XV Lung Ventilation

    Read More
    Public
  • A step closer towards scarless wound healing: Pharmaxis drug through Phase 1 trial

    Whilst key opinion leaders worldwide are following the Pharmaxis (ASX: PXS) story, Professor Fiona Wood has become an integral part of it.  Following the news out of Rochester University that their myelofibrosis drug, PXS-5505, has a potential significant disease modifying role in other cancers comes another key announcement for the company, this time regarding theirRead More
    Public
  • Rapid diagnostic kits drive Lumos revenue as FDA approval beckons for COVID tests

    Lumos Diagnostics’ (ASX: LDX) vision for decentralised diagnostic testing is slowly coming together with the Company releasing their full year results just one month after debuting on the ASX. Across the business, revenue increased 198% from FY20 to $25 million with its Commercial Services division the real MVP, delivering $22.7 million in revenue, a 188%

    Read More
    Public
  • Rhinomed puts new child-friendly COVID swab to the test

    Unless you’ve been living under a rock- we’re in a global pandemic. By now, you’ve probably had the pleasure of having your brain tickled through your nose via nasal swab, fretting that your annual winter cold is actually the plague.  Whilst most of us can handle the violation that is a nasal swab, testing children

    Read More
    Public
  • LiveTiles grows as employee experience becomes increasingly important

    With well over a year of working from home under our belts it’s safe to say that hybrid and remote work is no longer a temporary solution. Our new way of working has spurred the growth of some organisations providing solutions to enhance the digital working experience. LiveTiles (ASX: LVT) is one such company, creating

    Read More
    Public
  • Tackling the enduring epidemic taking place in the background of COVID-19

    With COVID dominating headlines for well over a year, you may not have noticed the worsening opioid crisis. Specifically in the United States where there has been a steep rise in overdose related deaths in the past 12 months. Data released by the National Centre for Health Statistics in July showed that in the year

    Read More
    Public
  • VEEM’s tech gets its sea legs with exceptional results in sea trials

    Think of VEEM Marine (ASX: VEE) as the team doing their best behind the scenes to make your experience better when lockdown ends and you finally board your yacht. Picture yourself: mimosa in hand, out on the ocean, enjoying the sun. Keeping that mimosa firmly in your hand and not spilled all over the deck

    Read More
    Public
  • ImpediMed receives FDA designation for dialysis device

    From the cochlear implant to pacemakers, medical devices have changed the way we treat and manage numerous conditions. Medtech company ImpediMed (ASX: IPD) saw a need in dialysis patients and sought to offer a better solution. Dialysis is the process of removal of water and waste products from the body to filter out toxins, and

    Read More
    Public
  • Quantum chips, biochips, hot chips, poker chips… Archer responds to media misgivings

    In a fumble of the facts, a popular Australian business masthead has been called out by one of the ASX’s hottest stocks over the past 12 months for factual errors in a piece yesterday titled “Archer Materials didn’t disclose Australian patent body’s objections”. The article made some market altering statements, publishing that Archer’s (ASX: AXE)

    Read More
    Public
  • Side hustle culture pushes Airtasker growth both locally and overseas

    With an ever growing side hustle culture and more time on our hands thanks to lockdowns, Airtasker (ASX: ART) is quickly becoming a household name.  The platform has claimed the title of Australia’s number one marketplace for local services. With their mission to empower people to realise the full value of their skills, more and

    Read More
    Public
  • Island Pharmaceuticals receives third patent for dengue fever drug

    Sorry COVID, there’s a slew of other diseases that require our attention as well. One of which is the highly contagious dengue fever. Joy. Transmitted by mosquitoes, dengue infects an estimated 390 million people each year. That number is set to rise as global warming sees mosquitoes travelling further than ever before. Treatment for those

    Read More
    Public
  • This ‘proptech’ is transforming the way we buy and sell homes

    Almost every industry has been forced to pivot and adapt to the increasingly digital world in the wake of COVID-19. Self proclaimed ‘proptech’, Openn Negotiation (ASX: OPN) offers a platform for the real estate industry to operate online. The Openn cloud-based software platform supports real estate agents to sell properties by facilitating negotiation, contracting and

    Read More
    Public
  • Cancer drug development company gathering momentum as more researchers worldwide take notice

    With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, aRead More
    Public
  • Blood test or crystal ball? Looking into the future of our health

    An estimated 1.2 million Australians are living with diabetes, a serious chronic disease with numerous complications and comorbidities including diabetic kidney disease (DKD). The risk factors for developing DKD are well known, but could we treat people better if we knew more about their personal risk factors, or predict the likelihood of future functional decline

    Read More
    Public
  • Austal – from where you’d rather be

    Your journalist would prefer to be on the sandy white beaches of Tahiti right now, sipping a cool mojito and sizzling in the sun.  But, with a long expired passport that won’t be renewed anytime soon, I’m bound to my inner city apartment.  Teasing me, and those locked down across the country is Austal Limited

    Read More
    Public
  • EMVision’s vision: Point-of-care diagnostic imaging for neurological conditions

    Time is of the essence when a stroke occurs. Each minute that a stroke patient goes without treatment, 1.9 million brain cells die. Early intervention is key and medtech company EMVision Medical Devices (ASX: EMV) wants to help get stroke treatment underway faster. Their point-of-care brain imaging platform allows for rapid diagnosis of neurological conditions

    Read More
    Public
  • Nutritional Growth Solutions reaching new heights with market expansion into China

    Nutritional Growth Solutions (ASX: NGS) is reaching new heights on their growth chart with expansion into global markets, confirming the launch of their proprietary Healthy Height® shake range in Chemist Warehouse in China. Addressing an overlooked subset of the nutritional supplement market, NGS creates clinically proven supplements to support healthy growth and development in children

    Read More
    Public
  • MDMA usage at University is through the roof as Emyria takes aim at mental health

    Harbouring more MDMA than music festival goers, the University of Western Australia (UWA) is leading the way in research around the use of MDMA as a psychedelic medication. Clinical drug development and care delivery company Emyria (ASX: EMD) has today announced a partnership with UWA, confirming access to their library of MDMA- like compounds developed

    Read More
    Public
  • Proteomics International to collaborate on world first blood test for endometriosis

    One in nine Australian women will suffer from endometriosis, a debilitating, chronic menstrual health disorder resulting in serious pain, fertility issues and reduced quality of life. The disease occurs when tissue similar to that within the lining of the uterus grows outside of the uterus in other areas of the body, commonly around the reproductive

    Read More
    Public
  • Aussie company SpaceLink to join the likes of Branson and Bezos

    In an age where CEOs can take to space in questionably shaped spacecraft, the demand for fast, reliable communications (so we can be reminded of how much money each minute burns) is growing. Electro Optic Systems (ASX: EOS) subsidiary company SpaceLink does just that. The Company has been selected by the Centre for the Advancement

    Read More
    Public
  • Identitii is dotting the i’s and crossing the t’s with their financial compliance tech

    You never forget your first, and neither will financial compliance tech company Identitii (ASX: ID8) which has hit the ground running with the newest fintech software, Overlay+, which has opened the door to a new stream of SaaS revenue.  The tech aims to simplify and automate financial crime compliance by making it easier to access

    Read More
    Public
  • Dosing complete, Pharmaxis progresses with skin scarring trials led by Professor Fiona Wood

    Our scars tell a story, whether it be grazed knees from the school yard or those mystery scrapes that make you wonder what on earth happened the night before.  More often than not these minor scars give us funny stories, laughs and reminders not to touch hot irons. But for more serious injury following events

    Read More
    Public
  • Looking to the future: Turning genetics into diagnostic tools for better health

    The one-size-fits-all approach to medicine is on its way out with the rise of personalised medicine. The development of technologies to individualise healthcare for each person holds much promise for tackling disease treatment and prevention. A prime example of this is the development of genetic testing for the BRCA genes. Inherited genetic mutations within these

    Read More
    Public
  • Hearing health to be prioritised under Government roadmap as Healthia expands into audiology

    The gaping dental shaped hole in the Australian healthcare system is a frequent point of contention and the more you look into it, the scope of Medicare coverage seems to narrow. Audiology is an essential service not entirely covered by Medicare, but that may soon change  Hearing health is a chronically overlooked aspect of our

    Read More
    Public
  • Gut happy! Medlab wants to change the way we treat depression

    There’s no doubt that we are living in extraordinary times. The COVID-19 pandemic has tested almost every aspect of our lives, our resilience, ability to organise and ability to adapt. With a drastic change in our way of living, the toll on our collective mental health has been profound. Beyond Blue estimates that over 3

    Read More
    Public
  • 4D Medical progresses with development of their dedicated lung diagnostics tech

    Every year traditional methods of lung diagnostics worldwide cost US $31 billion dollars. The arguably outdated technologies include the x-ray (invented in 1895), spirometry (invented in 1846) and CT (invented in 1971). Each has their own pros and cons, yet there remains a strong need for low dose, minimally  invasive, time efficient and cost effective

    Read More
    Public
  • No need to sugarcoat: Candy Club report sweet revenue increase

    Let’s face it. Candy and chocolate taste way WAY better than carrot sticks with hummus. And even if you swear by your rabbit food, the size of the global confectionery market speaks for itself. Estimated to be valued at USD $210.3 billion in 2019 and rising by a compound annual growth rate of 3.6%, the

    Read More
    Public
  • Would you like potato & gravy with that? Pure Foods Tasmania sales jump 70%

    Opening up the quarterly report from Pure Foods Tasmania (ASX: PFT), you are greeted by a stunning vista from where you’d rather be, good enough to rattle us locked down Victorians (please let us out please let us out please let us out).  I digress. Founded in 2015 to acquire, grow and develop premium food

    Read More
    Public
  • Tackling heart attacks with world first implantable monitoring device

    A heart attack can feel like literally anything. A sore arm, jaw pain, nausea… The list goes on. Difficulty in recognising a heart attack due to atypical symptoms increases for women, elderly and diabetics. The wide scope of symptoms can often result in costly emergency room visits and tests just to discover simple indigestion is

    Read More
    Public
  • Pup got itchy paws? You might want to remember this company’s name

    It wasn’t too long ago that I was in the shower, holding my squirming dog’s paws in a washing basket filled with an oatmeal concoction, whilst smearing peanut butter on the shower wall for her to lick. Why, you ask? Because my baby gets itchy paws (and I’m a great dog mom). Itchy paws and

    Read More
    Public
  • 1 in 4 babies in the US benefit from HeraMed’s pregnancy tech

    Medical data and technology company HeraMED (ASX: HMD) has today announced a partnership to accelerate their mission to revolutionise maternal care. The Company has entered into a paid pilot with Obstetrix Medical Group, one of the largest clinical providers in the US for both women’s and children’s health. Obstetrix, an affiliate of US $2.2 billion

    Read More
    Public
  • Diamonds are a pandemic’s best friend as Michael Hill sales sparkle

    Despite the enduring pandemic, lockdowns, restrictions and all the other crap that COVID has rained down upon us (I’m a VERY annoyed Melbournian this morning), retail has, for the most part, surprisingly stayed afloat, even thriving in some areas.  One of those areas is jewelry. Yep, diamonds remain a girl’s best friend, even when in

    Read More
    Public
  • Old trackies are comfy, old work ideas aren’t: how one company is revolutionising digital wellbeing

    Pyjama pant clad Zoom meetings are here to stay (I’m wearing spotty ones today, thanks for asking).  The new way we work is uncharted territory for many companies with managers forced to learn on the fly and adapt to the new normal. While we may be hitting our stride on the productivity side of things,

    Read More
    Public
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication

    Fresh off their recent distribution success of their intravenous, non-opioid based pain medication, AFT Pharmaceuticals (ASX: AFP) has ticked another box announcing the receival of regulatory approval for another form of the drug. The oral liquid form of Maxigesic is a non-opioid based analgesic and extension of AFT’s patented Maxigesic family of medications. The oral

    Read More
    Public
  • World going nuts for Aussie almonds as supply squeeze beckons from California droughts

    Readers would know, from the numerous references in my articles, that I’m an oat latte girl. That being said, I do appreciate a good almond cap. But you didn’t come here to read about my coffee order (or maybe you did… If so we’ll get along swimmingly), you came to read about Select Harvests (ASX:

    Read More
    Public
  • PharmAust partners with the Walter and Eliza Hall Institute to expand COVID-19 research

    Forging ahead with their lead drug candidate, PharmAust (ASX: PAA) is expanding on their COVID-19 program. Their new angle is to investigate the effects of monepantel (MPL) on human T-lymphotropic virus-1 (HTLV-1) infections in partnership with leading biomedical research organisation, the Walter and Eliza Hall Institute (WEHI), based in Melbourne. The HTLV-1 virus is a

    Read More
    Public
  • A slice of the After-pie: NZ’s leading BNPL is making strides in responsible credit

    New Zealand’s leading BNPL provider, Laybuy (ASX: LBY) has reported an impressive year across the board, proving that there is space yet to grow in the seemingly saturated sector.  Since its inception in 2017, Laybuy has gone from strength to strength with a seemingly well timed entry into the BNPL market.  Laybuy is now recognised

    Read More
    Public
  • LBT Innovations to present clinical data at leading industry conference

    Adelaide-based medtech company LBT Innovations (ASX: LBT) is moving nicely along the path to commercialise their flagship product, presenting clinical data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held online over the weekend. The ECCMID represents the largest global conference for clinical microbiology and is a unique opportunity

    Read More
    Public
  • Could this pharma company hold the answer to overuse of opioids?

    Pain management is one of the most fascinating arms of medicine. Post-operative pain management, even more so. Practitioners must strike a balance to ensure that acute pain doesn’t turn into chronic pain, and that a patient’s dependence on analgesia is temporary. The many issues with opioid based pain medications are well documented and, with a

    Read More
    Public
  • Green with envy: RotoGro rolls up purchase order for medicinal cannabis facility

    Touted as a miracle cure for just about any ailment, medicinal cannabis has been an interesting point of contention in healthcare for years now. The media hype around the stuff has increased, patient demand has increased, and global production is booming (legally). Canadian based Wolf Island Cannabis is currently constructing a cannabis cultivation facility in

    Read More
    Public
  • Bionomics granted Fast Track approval from FDA to study PTSD drug

    Once upon a time, stress ensured our survival. When faced with a dangerous situation our body responds instantly- heart rate increases, blood pressure climbs and muscles tighten as the body prepares to deal with the bear/ exam you’ve been presented with.  In the modern world we are faced with a disproportionately higher amount of exams

    Read More
    Public
  • ResApp study data published, further confirms app’s efficacy

    Confirming the efficacy and broader potential of their smartphone-based diagnostic app, ResApp Health Limited (ASX: RAP) clinical data referenced in a top academic publication has validated their app’s accuracy for respiratory diagnostics. Data from their Breathe Easy adult clinical study has been published in a peer-reviewed Nature partner journal, npj Digital Medicine. The study looked

    Read More
    Public
  • Trading 101: Top tips for new traders

    If you enjoy being actively involved in your investments, you may be interested in trading. Traders take advantage of small price movements to turn a profit. Starting on the right track is about understanding both the fundamentals of trading, and you as a trader. The best investment you can make is in your education. Do

    Read More
    Public
  • Curing sickness with viruses: How Imugene is using oncolytic viruses to treat cancer

    Despite the many advances in cancer therapy, we still haven’t quite hit the nail on the head, with cancer still responsible for 12% of all deaths worldwide each year.  The advancement of cancer therapies and the growing body of research is impressive to say the least, yet cancer patients of today do not fare much

    Read More
    Public
  • IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float

    With ever increasing bodies of medical research and demand for early disease detection climbing, it’s high time that we rethink diagnostic testing. The trend of having to wait three days to see if your pee is free of nasties is fraught with administration challenges and can delay treatment. Spend time in any medical establishment and

    Read More
    Public
  • Truscreen expands market for real time digital diagnostic testing device

    Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time.  Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test

    Read More
    Public
  • Italian kids growing taller as NGS shake things up with milestone sales

    Addressing a chronically overlooked group in the nutritional supplement space is working out well for Nutritional Growth Solutions (ASX: NGS). The supplement company is focused on improving the health of children aged 3-12 years old who do not meet the criteria for growth hormone therapy. A group that has been long overlooked in terms of

    Read More
    Public
  • 9 year old me would have really wanted Spacetalk’s latest smartwatch

    As someone who was 9 years old once upon a time and desperate for a Gecko, Firefly or TicTalk, I’m pretty sure that Spacetalk’s (ASX: SPA) Adventurer would have sent my primary school self a bit nuts.  Like a kid-on-red-cordial nuts. The kids with the cool spy girl looking devices were the envy of my

    Read More
    Public
  • First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

    Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir.   Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,

    Read More
    Public
  • Addressing growing healthcare demands with computer assisted medicine

    With more pressure than ever on the healthcare system, scalability is everything. How can we expand the system to meet increased demands by users? Pacific Knowledge Systems (ASX: PKS) is addressing this complex issue through their technology stack by providing software applications to better capture, apply and manage human expertise to enhance business performance and

    Read More
    Public
  • The blip in Cyclopharm’s plans for FDA approval

    There’s been a small bump in the road in Cyclopharm’s (ASX: CYC) plans to secure regulatory approval for Technegas™, their proprietary technology for lung imaging. Technegas™ comprises ultra-fine radioactive labelled carbon that is exposed to high heat to create a gas that can be inhaled by the patient. The gas allows for comprehensive imaging to

    Read More
    Public
  • Promising research for cancer diagnostic tests to be published

    Sadly, 1 in 7 women will be diagnosed with breast cancer at some stage in their life. That’s 1 in 7 mothers, daughters, aunties, girlfriends, wives, friends and nieces.  In the last 10 years, breast cancer diagnosis has increased by 36% and remains the second most common cause of death from cancer among females.  Health

    Read More
    Public
  • Promoting innovation: Empired wins multi-million dollar state government contract

    Digital technology transformation company Empired (ASX: EPD) does a lot. In a nutshell, the international tech company helps organisations transform and evolve through the best Microsoft technology enabling improved customer experiences, engaged staff and optimisation of cloud technologies. The Company has today announced that they have secured a $9 million contract with the Department of

    Read More
    Public
  • Respiri’s platform is taking asthma management beyond the clinic

    45% of people living with asthma have poor control of their condition which in turn, impacts their quality of life. Australia has one of the highest prevalence rates of asthma in the world with the disease affecting 2.7 million Australians, or 11% of the total population and costs us a massive $28 billion per year.

    Read More
    Public
  • Couch based online shopping sees Adairs bring forward Mocka settlement, set to re-invest

    Spending a mind numbing amount of time at home, as a locked down Victorian is wont to do sends you a bit loopy. It also might make that slightly squeaky dining chair drive you insane, or make you despise that old threadbare linen set you’ve had for years. Aussies have been feathering their nests with

    Read More
    Public
  • Over half a century since its launch, the contraceptive pill is getting a shake up

    Bloating, weight gain, mood swings, headaches. Just a handful of the not so lovely side effects bestowed upon women by the contraceptive pill. After half a century, I think we can all agree that the pill is long overdue for a shake up. With more women than ever increasingly aware of what they put into

    Read More
    Public
  • Paradigm’s study could give options to those with this rare incurable disease

    Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase 2 study of their flagship drug, pentosan polysulfate sodium (PPS) in patients with Mucopolysaccharidosis type VI (MPS VI). A big word to digest on a Friday morning, I know. The inherited disease is caused by

    Read More
    Public
  • Move over x-ray: 4D Medical’s respiratory scanning tech could be the new standard in imaging

    Invented in 1895 and becoming the standard in the early 1900s, the x-ray has long been the backbone of many medical diagnoses. The relatively unchanged technology has been commonplace for decades, but medtech company 4D Medical (ASX: 4DX) is rethinking the way we diagnose respiratory issues with their proprietary XV Technology™ and Permetium preclinical scanner. 

    Read More
    Public
  • Spray-on skin revenue exceeds initial forecasts

    The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher

    Read More
    Public
  • Goop might have been right…

    The keto diet is proving to be more than just another “It” diet touted by Goop with interesting research showing that it may have a place in cancer treatment. Eating a keto diet puts the body in a state of ketogenesis where instead of running off glucose based energy, the body is fueled by fats

    Read More
    Public
  • IPO Watch: Gefen Technologies to list on ASX with digital marketing platform for agents

    With initial plans to list in the Australian market last year furloughed by the pandemic, Israeli tech company Gefen Technologies is finally joining the dozen Israeli companies on the ASX, having closed their $25 million IPO at the end of last month. Israel is renowned for their ‘start up culture’, especially in tech, having produced

    Read More
    Public
  • How Noxopharm is overhauling the way we approach cancer treatment

    Traditional chemotherapy and radiotherapy have long been the standard of care for cancer treatment, but it’s no secret that there are numerous, debilitating side effects to a patient’s physical and mental health. Both are oftentimes ineffective with several cancers exhibiting poor responsiveness to traditional treatment.  Clinical-stage drug development company Noxopharm (ASX: NOX) is addressing this

    Read More
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children

    A hot topic in medical research at the moment, medicinal cannabis studies are being carried out for seemingly any and all ailments. One such trial being run by the Murdoch Children’s Research Institute (MCRI) is extending efficacy studies of cannabidiol medicine to children with intellectual disability that exhibit severe behavioural problems. To facilitate these studies,

    Read More
    Public
  • Pharmaxis Investor Briefing – Cancer Treatment Clinical Trials

    On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees. Topics discussed in the briefing and question time included: Clinical trial stage progress and timelines; Anticipated news flow for 2021-2022; Commercial opportunities being explored in collaborationRead More
    Public
  • Mad Paws to acquire Waggly Club, our office dog approves

    Feeding our office dog and many other pups Australia wide with their subscription meal service, Dinner Bowl, it’s safe to say Mad Paws (ASX: MPA) understands the subscription market. The Company has today announced the acquisition of one of Australia’s largest dog treats and toys subscription business, Waggly Club. Since its inception when founded by

    Read More
    Public
  • Strong sales continue for ZOLEO satellite messaging device

    Beam Communications (ASX: BCC) is enjoying the continued success of their satellite messaging device ZOLEO and has announced that they have received new orders for 22,000 of them. Sales have remained strong since ZOLEO’s launch in December 2019 with the device filling a previously unmet need for an affordable, compact and clever satellite messaging device.

    Read More
    Public
  • Could Dimerix be first to market with their innovative kidney disease drug?

    Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has today announced that their current Phase 3 drug for kidney disease has been awarded an Innovation Passport and the Innovative Licensing and Access Pathway (ILAP). The designation is awarded by the UK Medicines and Healthcare products Regulatory Agency and is designed to accelerate development of promising medicines to

    Read More
    Public
  • Openn Negotiation proptech IPO to bring transparency to real estate market

    The slimy sales tactics of prickly real estate agents may be in need of review with Australian property technology company Openn Negotiation set to debut on the ASX on Friday, 11 June.  A “proptech” company, Openn uses technology that aims to provide the best possible property sales outcomes for the seller, buyer and real estate

    Read More
    Public
  • Smart pain assessment app now used by more than half of Australia’s residential aged care providers

    Intelligent pain assessment company Painchek (ASX: PCK) is eager to become the new standard of care in aged care settings, today announcing that licensed agreements for their platform’s use now encompass 60% of Australian aged care providers. PainChek’s mobile based pain assessment tool uses AI and facial recognition software to objectively automate and quantify pain

    Read More
    Public
  • PharmAust receives ethics approval just in time for Big Freeze

    There is nothing fun about plunging into freezing cold ice water during a cold Melbourne winter. However, each year, bold celebrities participate in the annual ‘Big Freeze’ at the Melbourne Cricket Ground before the Melbourne vs Collingwood AFL clash on the Queen’s Birthday weekend.  The event, run by FightMND is designed to raise funds for

    Read More
    Public
  • ‘Working from home’ here to stay as productive Australians focus on wellbeing

    Among the many unknowns to emerge from the pandemic, the working from home phenomenon has plagued executive management but questions as to whether it would become the norm have been categorically answered with a resounding YES. Surveys have shown that working from home improves productivity and contributes to a better work life balance. Not having

    Read More
    Public
  • Genetic Technologies launches AI-based COVID Risk Test

    Personalised medicine is quickly becoming the new standard of healthcare thanks to the ease of genetic testing and technological advancements. Genetic Technologies (ASX: GTG) is pioneering a preventative, individualised approach to the COVID-19 pandemic through their experience in genomics and AI driven preventative health. Having already created genetic testing kits to predict breast and colorectal

    Read More
    Public
  • Avecho Biotechnology expands their proprietary drug delivery system to livestock

    Necessity is the mother of all invention, and seeing an opportunity, Avecho Biotechnology (ASX: AVE) has set about innovating a new livestock feed additive. The development of a new feed additive for animal use comes in anticipation of the European Union’s impending ban on livestock feeds with zinc oxide levels above a certain level. Zinc

    Read More
    Public
  • ZOLEO’s location tracking eliminates the need to drink piss, Bear Grylls thrilled

    Clunky satellite phones reminiscent of the bulky Nokia’s you’d carry around in the 90’s could soon become a thing of the past with Beam Communications’ (ASX: BCC) sexier tech offering. Beam’s joint venture company ZOLEO is well and truly changing the satellite phone game for adventurers the world over. The ZOLEO Satellite Communicator is an

    Read More
    Public
  • Food prototype success for Wide Open Agriculture’s plant-based proteins

    As someone with a penchant for oat milk lattes, Wide Open Agriculture’s (ASX: WOA) announcement today was music to my ears.  The regenerative food and agriculture company develops and distributes food products with a focus on conscious consumers.  They have today announced the results of a three month intensive research exercise conducted at Curtin University

    Read More
    Public
  • From A to B: Traffic Technologies is improving road safety in Victoria

    The removal of level crossings across Victoria has been a welcome change for Melbournians who have been reaping the benefits of smoother flowing traffic and less of that annoying, incessant ‘ding ding ding ding’ that we all despise. So far the Victorian Government’s “Big Build” program has seen the removal of 46 of 75 level

    Read More
    Public
  • 🎵 The knee bone’s connected to the… collagen rope device (?!)

    Regenerative medicine company Orthocell (ASX: OCC) has been granted patents from both China and Hong Kong for their proprietary novel CelGro® collagen rope device.  The addition of these two new patents means that the device is now patented across five jurisdictions including the US and Australia. The IP protection is integral to Orthocell’s commercialisation plans. 

    Read More
    Public
  • Investing 101: Five top tips for new investors

    We know that the share market can be confusing to navigate, and investing for the first time can be daunting. Before you start investing it’s important to understand some of the fundamentals of how the share market works as well as your preferences as an investor. We have put together our 5 top tips for

    Read More
    Public
  • Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status

    The commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug Administration (FDA) raising fresh questions to late-stage drug development company, Paradigm Biopharmaceuticals (ASX: PAR). The FDA response related to Paradigm’s application for Investigational New Drug status to be granted for their focus compound, Pentosan Polysulfate

    Read More
    Public
  • Zip expands to Europe and Middle East with further strategic acquisitions

    Zip Co’s (ASX: Z1P) global expansion plans are being realised with the Company today announcing the next steps for their push into overseas markets through the outright acquisitions of European BNPL provider Twisto Payments, and UAE-based BNPL leader Spotii Holdings. The move aligns with Zip’s strategic acquisitions plan. Both companies have been integrated into Zip’s

    Read More
    Public
  • Plenty of fish in the sea: Ridley to sell Tasmanian aquaculture facility

    Australia’s largest commercial provider of animal nutrition solutions, Ridley Corporation (ASX: RIC) has today announced the sale of their Tasmania extrusion and feed production facility. The sale of the facility to Skretting Australia will put $54.85 million into Ridley’s pocket and is expected to be finalised in the first half of FY22. The Company cites

    Read More
    Public
  • My Food Bag revenue increases as hungry Kiwis seek diet variety outside of ‘fush and chups’

    Contrary to popular belief, the Kiwis do not only eat ‘fush and chups’. Just like us Aussies, our neighbours do in fact eat a wide and varied diet not dissimilar to ours. My Food Bag (ASX: MFB) is one company delivering fresh ingredients across New Zealand in the form of meal kits. The Company has

    Read More
    Public
  • IPO Watch: Argenica Therapeutics developing drugs for brain recovery

    Every 19 minutes someone has a stroke. In 2019 that was 13 million people globally. During a stroke, the lack of oxygen caused by the blockage of blood vessels kills 1.9 million brain cells per minute. The medical interventional methods available to stroke patients are limited and focus on removing the clot chemically or mechanically.

    Read More
    Public
  • Applyflow sales rise as one-click apply emerges as the future of recruitment

    Many graduates lament over the old, clunky and annoying recruitment platforms and job boards that they are forced to trawl in the hopes of getting a foot in the door of their chosen industry. It’s no surprise that 60% of applications get abandoned due to complexity. It’s high time that something newer, streamlined and just

    Read More
    Public
  • Mosquitoes suck. Island Pharmaceuticals does not.

    Fun fact: The word mosquito actually translates to “little fly” in Spanish. Although you’re more likely to hear them called a whole host of profanities in many households. Little f***ers. If the blood sucking pests weren’t annoying enough, they carry diseases like dengue fever. An estimated 390 million people are infected with dengue each year.

    Read More
    Public
  • Nutritional Growth Solutions launches new snack bar to grow kids taller

    Ever noticed how the nutritional supplements that line the aisles of supermarkets and pharmacies are either for adults or children under the age of three? What about the kids in the middle? Key development continues well past the age of three and optimal nutrition plays a huge role in reaching developmental milestones. Addressing this long

    Read More
    Public
  • Medtech device sales a key step forward for LBT Innovations

    LBT Innovations (ASX: LBT) has this morning announced the sale of two of their AI pathology instruments. The Adelaide based med tech company is a leader in medical technology automation through the use of artificial intelligence.  Their flagship product is the APAS® Independence. The Automated Plate Assessment System (APAS®) technology integrates AI to automate culture

    Read More
    Public
  • BWX to acquire beauty and wellness online retailer Flora & Fauna

    The clean and natural beauty movement is well and truly mainstream. The rise of conscious consumerism has seen the natural beauty and wellbeing market grow by over 12% annually.  The proliferation of small brands that gain cult following are eroding the market share of the big players.  BWX (ASX: BWX) is a leading wellness business

    Read More
    Public
  • Strategic Elements: Homegrown innovation to quell invisible threats

    The threat of chemical, biological, radiological and nuclear (CBRN) attacks on both military and civilian populations is growing.  As if we didn’t already have enough to worry about. Anxiety riddled, chronic overthinkers and savvy investors alike will be glad to know that Strategic Elements (ASX: SOR) are working on solutions for autonomous sensing and search

    Read More
    Public
  • Lucapa found a 138 carat diamond, Danny Archer jealous

    Diamonds may very well be an investor’s best friend this morning with the Lucapa Diamond Company (ASX: LOM) announcing the finding of the 24th 100+ carat diamond from the Lulo alluvial diamond mine in Angola. The 138 carat stone brings the Company’s tally of 100+ carat diamonds found this year alone to 7. It is

    Read More
    Public
  • Delta Drone expands training operations, targets Namibia

    If you ever needed confirmation that we really are living in the future, all you need to do is look through the ASX listed tech companies and what they’re doing. The scope of our technological capabilities is downright impressive.  One company that might be of interest is Delta Drone International (ASX: DLT), a global Drones-as-a-Service

    Read More
    Public
  • IPO Watch: Australian Clinical Labs to list after successfully raising $408m

    In and amongst the slew of resource based IPOs vying for listing this month is Australian pathology company Australian Clinical Labs (Proposed ASX code: ACL).  The Company is hoping to join the likes of their ASX-listed competitors Sonic Healthcare (ASX: SHL) and Healius (ASX: HLS) later this month with an IPO Offer Price of $4

    Read More
    Public
  • How Incannex is helping you catch some zzz’s

    Unsurprisingly, four out of ten adults experience regular poor sleep. We all know the consequences of a bad night’s rest on our health, performance and mood, as well as the crippling caffeine addiction that develops. *Sips double shot oat milk latte*  People with Obstructive Sleep Apnoea (OSA) have it worse. OSA is characterised by partial

    Read More
    Public
  • Explain Like I’m 5: Trading vs Investing

    If you explore the world of the share market for more than two minutes you’re bound to come across the words “investing” and “trading”. But what is the difference between the two of them and how do you decide which is right for you? Let’s start with the basics. What is trading?  Trading involves frequent

    Read More
    Public
  • Archer Materials are progressing with their chips, not the salt and vinegar kind

    I’m not sure what’s harder- wrapping your head around what Archer Material’s (ASX: AXE) does, or comprehending the value of the market that they are tapping into. A market which currently sits at a whopping USD $400 billion per annum, and is forecast to reach over USD $1 trillion by 2030. Have I got your

    Read More
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment

    Jennie Young was one of the first patients to receive Veyonda, Noxopharm’s (ASX: NOX) proprietary drug. Administered on compassionate grounds, her doctors believe that she responded to it positively. She had leiomyosarcoma, a rare cancer that affects smooth muscle tissue. Soft tissue sarcomas like hers have limited treatment options with only 14% responding to chemotherapy. 

    Read More
    Public
  • Top of the class: Rhythm’s latest study results outperform the standard

    Colorectal cancer is the third most commonly occurring cancer in men, and the second in women. Yet every year 130 million people around the world between the ages of 50-74 remain unscreened. Rhythm Biosciences (ASX: RHY) are not complacent with that number and are working on an innovative solution to aid diagnosis of this major

    Read More
    Public
  • This company’s advanced 3D printing product could become industry standard

    From dental devices to jet engines, 3D printing is quickly becoming mainstream. Its use is moving well beyond prototyping and toys, towards industrial applications. Leading the way in the commercialisation of industrial 3D printers is AML3D (ASX: AL3), and their market update today proves that they plan on staying ahead of the game. The Company

    Read More
    Public
  • Will this sporting tech IPO be a Hit?

    Injury is inevitable in both elite and recreational sport. Most cuts, bruises, strains and tears can be remedied in a relatively short time frame with minimal ongoing issues. Traumatic brain injuries are quite the opposite. They can be debilitating, life altering and career ending. Following increased researcher interest and the findings of multiple studies, the

    Read More
    Public
  • Can Medibio’s software redefine mental health diagnostics?

    Mental illness will have an impact on 45% of Australians at some point in their lifetime. While the world is becoming increasingly aware of mental health conditions, little is being done to redefine the diagnostics. Currently, the gold standard in the diagnosis of mental illness is The Diagnostic and Statistical Manual of Mental Disorders (DSM5).

    Read More
    Public
  • Ingenia are not taking a break, so you can

    Australian’s are slowly pulling down their masks to embrace a new normal in the wake of the pandemic. Travel, at least domestically, is returning to pre-covid levels, a welcome change for those working in and around one of the hardest hit industries. Amongst those relieved companies is Ingenia Communities (ASX: INA). The Company is welcoming

    Read More
    Public
  • This company is really neat

    Craft beverage ‘accelerator’ Mighty Craft (ASX: MCL) has been getting Aussies tipsy on beer, spirits and now, whiskey.  The Company has today announced the appointment of two guys to their ‘Whiskey Acceleration Team’ (a trivia night team name winner for sure) whose job it is to get you buzzed.  Chris Malcolm and George Campbell are

    Read More
    Public
  • How three companies are collaborating to tackle an epidemic

    Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs).  The announcement represents significant market expansion, with Unitaid committing

    Read More
    Public
  • Do you really own your shares?

    The global pandemic affected almost every aspect of modern life, and the stock market was no exception. The stock market crash early in 2020 saw an influx of retail investors and a huge increase in the number of accounts opened on trading apps. While investing is almost always a positive step towards financial freedom, experts

    Read More
    Public
  • Latitude IPO successful but how big will the exit selldown be?

    The saying ‘third time’s a charm’ rings true for financial services company Latitude (ASX: LFS) who finally made their entrance to the public market last week after cementing themselves as the biggest ASX float of 2021   This year’s offering marked Latitude’s third attempt at an IPO. Their first attempt was stalled in 2018 by investor

    Read More
    Public
  • PharmAust is putting a leash on canine cancer, and COVID-19

    From high rise city apartments to the rolling hills of the countryside, you’re likely to find a dog or two snuggled up on the living room couch. Studies have proven what us dog loving people already know- that the human-canine bond is special. Owning a dog reduces stress, alleviates anxiety and even can prolong your

    Read More
    Public
  • How 4DMedical is changing the medtech game post COVID

    While we are seemingly on the back-stretch of the COVID-19 pandemic, increased medical awareness has changed how we diagnose respiratory diseases with medtech company 4DMedical (ASX: 4DX) leading the charge. Their proprietary FDA/TGA approved, patented respiratory imaging platform, XV Technology turns sequences of x-ray images into four-dimensional, quantitative data to improve and accelerate diagnostic accuracy.

    Read More
    Public
  • High-touch, high-quality maternity care could soon become standard in major hospitals

    Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which

    Read More
    Public
  • New Anatara trial to tackle anxiety, stress and depression with diet supplement

    Working in conjunction with the CSIRO, Anatara Lifesciences (ASX: ANR) has received ethics approval to apply their diet supplement 3FDC to a new area of medicine, seeking to evaluate the compound’s effects in adults with moderate anxiety, stress and depression. 3FDC is one of the constituents of Anatara’s flagship supplement (GaRP) intended for the treatment

    Read More
    Public
  • Could Creso’s psychedelics solve Australia’s $10.6 billion problem?

    According to the Australian Department of Health, half of us will experience some form of mental illness in our lifetime. Treatment is somewhat limited to prescription medications and psychotherapy. However, the current mental health crisis has seen researchers and practitioners alike wondering- is there a better way to approach these frighteningly common conditions? Enter psychedelics,

    Read More
    Public
  • Millenials get happy! Alterra is making your smashed avo dreams come true

    Progressing their next-gen 300-hectare avocado project in Western Australia, sustainable agriculture specialist Alterra (ASX:1AG) could soon be extending the live-at-home lives of millenials that continue to prioritise smashed avo cafe breakfasts ahead of financial independence. The Company has released an update today on the progress of their flagship 300-hectare avocado project. The Carpenters Project, located

    Read More
    Public
  • The rising BNPL star giving Afterpay a run for their money

    Zip Co (ASX: Z1P) is nipping at the heels of Australian BNPL leader Afterpay (ASX: APT), based on today’s announcement of their Q3 results. Despite the pandemic, Zip has managed to maintain momentum and deliver strong results across Australian, New Zealand, UK and US markets bolstering itself as one of the fastest growing BNPL leaders.

    Read More
    Public
  • LBT Innovations sets sights on US healthcare market with AI-powered pathology

    Adelaide-based medical technology company LBT Innovations (ASX: LBT) is lining up distributors in the lucrative US healthcare market for their pathology screening tech which is driven by artificial intelligence to maximise testing throughput in labs, providing healthcare professionals with accurate results faster.    The Automated Plate Assessment System (APAS®) is a pathology AI device which automates

    Read More
    Public
  • Encouraging results from Recce Pharmaceuticals in fight against drug resistant bacteria

    As the world prepares for a myriad of drug-resistant bacteria following decades of over-prescribing and improper use of antibiotics, Recce Pharmaceuticals (ASX: RCE) has reported encouraging clinical results in response to multi drug resistant bacterial sinusitis infection. Following on from promising results observed in animal studies, a 59-year-old male was treated with the compound R327

    Read More
    Public